Funding & Investment - Celine Halioua's company has secured $135 million in funding from prominent investors [1] Product Development & Regulatory Approval - The company is developing canine longevity pills [1] - The company anticipates receiving its first conditional approval from the FDA (Food and Drug Administration) next year [1] Industry Focus - The company's focus is on extending the lifespan of dogs [1]

WATCH: This Next Billion-Dollar Startup Makes Longevity Drugs For Dogs #BillionDollarStartups https://t.co/lpMmB19VYh ...

What if dogs could live longer? Celine Halioua has raised $135 million from top investors to develop canine longevity pills—and expects to get her first conditional approval from the FDA next year. https://t.co/1XleCUxSCn (Photo: Ethan Pines For Forbes) #BillionDollarStartups https://t.co/GuBd0QAxuj ...

Company Overview - Loyal 公司致力于研发延长犬类寿命的药物 [1] - Loyal 公司已从顶级投资者处筹集 1.35 亿美元资金 [1] Product Development - Loyal 公司正在开发犬类长寿药丸 [1] Funding - Loyal 公司已获得 1.35 亿美元（$135 million）的融资 [1]

What if dogs could live longer? Celine Halioua has raised $135 million from top investors to develop canine longevity pills—and expects to get her first conditional approval from the FDA next year. https://t.co/XPMe2lfUUh (Photo: Ethan Pines For Forbes) #BillionDollarStartups https://t.co/QMtkigu7m7 ...

Dogs don’t live long enough. The family Lab might make it to 14; bigger beasts like Bernese mountain dogs are lucky to see 9. Celine Halioua thinks they deserve a few more years. https://t.co/7N8N6wbO7H #BillionDollarStartups ...

Longer Leash On Life: Inside The Dog Longevity Startup https://t.co/ewZI3hIKmz (Photo: Ethan Pines for Forbes) #BillionDollarStartups https://t.co/Uw6ry11AYj ...

Funding & Investment - Celine Halioua's company has raised $135 million from top investors [1] Pharmaceutical Development - The company is developing canine longevity pills [1] - The company expects to get its first conditional approval from the FDA next year [1] Industry Focus - The focus is on extending the lifespan of dogs [1]

Longer Leash On Life: Inside The Dog Longevity Startuphttps://t.co/JYZBlAHfTr https://t.co/zlgkkATgsp ...

Core Insights - Jupiter Neurosciences, Inc. has launched Nugevia MND, a supplement aimed at enhancing cognitive function and supporting brain health, tapping into the $8 trillion longevity and wellness markets [1][4] - Nugevia MND combines JOTROL, a proprietary resveratrol-based platform, with NovaSOL Curcumin to target neuroprotective pathways and improve cognitive resilience [2][4] - The product is positioned to generate high-margin revenue by appealing to aging populations concerned about cognitive decline, while also complementing Jupiter's pharmaceutical pipeline [4][8] Product Details - Nugevia MND is designed to improve memory, clarity, executive function, and support mitochondrial function in brain cells, while reducing neuroinflammation and oxidative stress [7][8] - The supplement will be available through direct-to-consumer e-commerce platforms starting Fall 2025, with a recommended daily regimen of two capsules [4] Strategic Importance - The launch of Nugevia MND represents a strategic move for Jupiter to leverage its expertise in central nervous system (CNS) therapeutics within the consumer health market [3][4] - Insights gained from consumer use of MND and biomarker data from ongoing clinical trials will inform future cognitive health programs [3][4] Scientific Foundation - JOTROL has demonstrated over nine times higher bioavailability compared to traditional resveratrol products, addressing previous issues of poor absorption and gastrointestinal side effects [9][10] - The product line aims to bring clinical-grade science into the wellness space, supporting mental clarity and cellular energy [11]